Walmart (NYSE:WMT | WMT Price Prediction) and Johnson & Johnson (NYSE:JNJ) just delivered results that show two defensive giants pulling on very different levers.
Walmart posted $175.68 billion in Q1 FY27 revenue with omnichannel firing on all cylinders. J&J leaned on its pharma pipeline to grow Q1 2026 sales 9.9%. Both beat estimates. The playbooks could hardly look more different.
Retail Flywheel Meets Pharma Firepower
Walmart’s quarter was a story of stickiness turning into leverage. U.S. comp sales rose 4.1% ex-fuel on 3.0% transaction growth, and global eCommerce jumped 26%, now 23% of sales. Advertising climbed 37%, and marketplace sales surged nearly 50%, the best in ten quarters.
Upper-income households keep trading in, and CEO John Furner credited “innovative technologies, driving productivity through automation, and growing higher-margin commerce solutions.” Free cash flow turned negative at -$1.95 billion as capex jumped 34%. That signals investment in future throughput capacity.
J&J’s engine ran on drugs. Innovative Medicine rose 11.2% to $15.43 billion, with DARZALEX at $3.96 billion (+22.5%) and TREMFYA up 68.3%, absorbing the STELARA biosimilar shock. MedTech added 7.7%, led by cardiovascular. CEO Joaquin Duato called the pipeline “unrivaled,” pointing to fresh approvals like ICOTYDE and VARIPULSE Pro.
One Widens The Store. One Prunes The Portfolio.
| Lens | Walmart | J&J |
| Core Bet | Omnichannel + ads | Oncology and immunology drugs |
| Growth Engine | eCommerce +26% | TREMFYA +68.3% |
| Key Vulnerability | Tariffs, fuel (250 bps hit) | STELARA erosion (-59.7%) |
| Capital Move | New $30B buyback | 64th straight dividend hike |
Walmart is widening: more delivery, more marketplace sellers, more ad inventory through VIZIO.
J&J is narrowing, planning a DePuy Synthes orthopaedics spinoff within 18 to 24 months and pouring over $1 billion into cell therapy manufacturing. Different visions of defense.
The Next Test Is Whether Consumers Hold Up
With University of Michigan consumer sentiment at 44.8, near recessionary territory, I want to see whether Walmart’s upper-income share gains survive a broader pullback.
J&J faces a nearer catalyst: prediction markets currently price a 92.5% probability of a Q2 EPS beat, with Innovative Medicine consensus clustering around $16.2 to $16.65 billion. Guidance was already raised to $11.45 to $11.65 adjusted EPS for the year.
Why I Lean Toward J&J At These Prices
Both are quality. You are paying very differently for them.
Walmart trades at a trailing P/E of 40 with a 0.85% yield, while J&J sits near 30 with a 2.01% yield and 21.8% profit margins versus Walmart’s 3.14%.
J&J shares are already up 25.56% year to date, and I still find the pipeline math more compelling than paying 39 times forward earnings for a retailer with negative free cash flow this quarter. Walmart offers brand-driven compounding for investors patient with tariff noise. J&J’s combination of yield, margins, and pipeline stands out at these valuations.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks